Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Trial details
- Registry ID
- NCT05184335
- Drugs studied
- Brilaroxazine
TrialRedline tracks 2 clinical trials sponsored by Reviva Pharmaceuticals: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335 | Brilaroxazine | Recruiting | 2025-02Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderNCT01490086 | RP5063, aripiprazole | Completed | 2013-03Actual |
Names as written in the registry records.